Salix Pharmaceuticals News
Roche recently announced positive data on its ulcerative colitis (UC) candidate, etrolizumab (RG7413), from EUCALYPTUS, a phase II induction study
Merck KGaA presented detailed results on its oncology candidate L-BLP25, from the phase III study, START.
UCB presented data from a study showing the effect of Neupro on cardiovascular measures in patients with restless legs syndrome.
InPlay: Salix Pharma announces statistically significant results for Budesonide foam in the treatment of active mild to moderate ulcerative proctitis or ulcerative proctosigmoiditis in two pivotal phase 3 studiesMay 22
Salix Pharmaceuticals Announces Statistically Significant Results for Budesonide Foam in the Treatment of Active Mild to Moderate Ulcerative Proctitis or Ulcerative Proctosigmoiditis in Two Pivotal Phase 3 StudiesBusiness Wire May 22
Salix Pharmaceuticals, Ltd. today announced the successful completion and outcome of two pivotal Phase 3 studies to evaluate the efficacy and safety of budesonide foam in the treatment of active mild to moderate ulcerative proctitis or ulcerative proctosigmoiditis .
GLP0634 will now be developed for Crohn's disease as well.
Novartis (NVS) recently announced positive results on Afinitor, from a phase III trial, BOLERO-3.
Novo Nordisk recently announced positive phase III data on its hemophilia B candidate, N9-GP, from the paradigm 2 study.
The acquisition is expected to be accretive to Actavis' 2014 earnings per share by more than 30%.